Nov 25, 2025
FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer“Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study. First...
Nov 25, 2025
Duke researchers discover new origin of small cell lung cancer in study“DURHAM, N.C. (WTVD) — Small cell lung cancer is one of the most aggressive and deadly forms of lung cancer commonly associated with smoking. Now, researchers at Duke Health have uncovered a...
Nov 25, 2025
WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care“CancerNetwork® covered the newest clinical trial findings that researchers presented at the meeting. Here are the top 5 takeaways that may impact lung cancer management.” Impact of Anticoagulant and Antiplatelet...
Nov 25, 2025
New Summit data clouds approval pathway in lung cancer“A combination of ivonescimab and chemotherapy didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.” First-in-human trial shows promising results for...
Nov 25, 2025
The quality of patient decision aids for lung cancer screening: Results from an environmental scan“Shared decision making is recommended for lung cancer screening (LCS) by professional organizations and payers. Patient decision aids can be used to support shared...
Nov 25, 2025
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer“SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ — Innovent Biologics, Inc....
More News and Updates